Micronised Progesterone vs Norethisterone for Perimenopause: Mood, Risk, and Prescribing
Comparing Utrogestan (micronised progesterone) and norethisterone for perimenopause. Mood effects, breast cancer risk, who is prescribed which, and key differences.
Why the Type of Progestogen Matters
Women with a uterus who take oestrogen as part of HRT must also take a progestogen to protect the uterine lining from the proliferative effect of oestrogen alone. Without progestogen protection, unopposed oestrogen significantly increases the risk of endometrial hyperplasia and endometrial cancer. The progestogen component is often where women experience the most troublesome side effects of HRT, and the type of progestogen used matters enormously. Micronised progesterone (brand name Utrogestan in the UK) is a body-identical form, structurally identical to the progesterone the body produces naturally. Norethisterone is a synthetic progestogen, a progestin derived from testosterone, which has a different receptor binding profile and a different side effect burden. Understanding the distinction between these two helps women make informed decisions with their prescribers and explains why women who struggle with one type of progestogen should not give up on HRT entirely before trying an alternative.
Micronised Progesterone: Mechanism and Benefits
Utrogestan contains micronised progesterone in peanut oil capsules, and is the most commonly prescribed progestogen alongside body-identical transdermal oestrogen in current UK menopause practice. Progesterone acts on the GABA receptor system in the brain, producing a calming, anxiolytic, and sleep-promoting effect. Many women report improved sleep quality when taking Utrogestan, and this is a genuine pharmacological effect rather than a placebo response. The recommended dose for endometrial protection is 200 mg nightly for twelve to fourteen days per cycle (sequential regimen) or 100 mg nightly continuously. Taking Utrogestan vaginally rather than orally produces lower systemic blood levels with equivalent endometrial protection, reducing the sedative effect for women who find the oral dose leaves them groggy in the morning. The progesterone receptor selectivity of micronised progesterone means it avoids many of the androgenic, glucocorticoid, and mineralocorticoid effects that cause mood disturbance and other side effects with synthetic progestogens.
Norethisterone: What It Is and How It Differs
Norethisterone is a synthetic progestogen that was used extensively in older HRT formulations, including combined tablets such as Prempak-C and some sequential combined preparations. It has androgenic properties, meaning it can produce testosterone-like effects including acne, increased body hair in some women, mood changes resembling PMT-type symptoms, breast tenderness, headaches, and in some women, worsening of depressive symptoms. It is still prescribed in some combined pill-style HRT formulations and as a standalone progestogen, and it remains on formulary because it is inexpensive, effective for endometrial protection, and well established in clinical practice. Some women tolerate norethisterone without significant side effects. However, for those who experienced PMS or PMDD in their reproductive years, or who are already dealing with perimenopause-related mood instability, norethisterone often worsens the situation. It is also available as a continuous combined preparation in Noriday and as part of sequential products such as Trisequens.
Breast Cancer Risk: What the Evidence Shows
The question of progestogen type and breast cancer risk has been one of the most debated areas in menopause medicine. The 2019 Million Women Study and subsequent analyses suggested that all progestogens added to oestrogen increase breast cancer risk compared to oestrogen alone, but that the magnitude of increased risk varies by progestogen type. Synthetic progestogens, including norethisterone, were associated with a higher additional risk than micronised progesterone. The E3N French cohort study, following over 80,000 women for up to twelve years, found that oestrogen combined with synthetic progestins carried a statistically significant increased risk of breast cancer, whereas oestrogen combined with micronised progesterone did not show a statistically significant increase. This has influenced UK prescribing guidance, with most menopause specialists now recommending body-identical micronised progesterone as the preferred progestogen for the majority of women. For women with a personal or family history of breast cancer, the choice of progestogen is particularly important and should be made in conjunction with an oncologist or specialist menopause clinician.
Who Receives Which Progestogen and Why
Micronised progesterone is now the first-line recommendation for most women starting HRT in the UK, consistent with updated NICE guidance and British Menopause Society recommendations. It is particularly recommended for women with a history of mood sensitivity to progestogens, PMS, PMDD, or perimenopausal mood instability. Its superior side effect profile and more favourable breast cancer risk data make it the better choice for the vast majority of women. Norethisterone continues to be prescribed in certain clinical situations. Some women find the sedative effect of Utrogestan too pronounced even at lower doses or with vaginal administration, and a non-sedating synthetic alternative is preferred. Cost considerations can influence prescribing, with norethisterone-containing combined products being cheaper than separate body-identical preparations in some formularies. Women who have a Mirena coil (levonorgestrel-releasing IUS) can use it as their progestogen component with oestrogen-only transdermal therapy, which is another option that avoids systemic progestogen side effects for many women.
What to Do If You Are Currently on Norethisterone
If you are currently taking an HRT regimen that includes norethisterone and you are experiencing mood disturbances, breast tenderness, acne, or other progestogen-related side effects, requesting a switch to micronised progesterone is a reasonable and evidence-supported conversation to have with your prescriber. This involves changing from a combined product to separate transdermal oestrogen and Utrogestan capsules, which is now a standard prescribing approach. Your GP may need guidance on the equivalent dose and regimen, and it is useful to be aware that the typical Utrogestan dose for a sequential regimen is 200 mg taken orally at bedtime for twelve to fourteen days per cycle, or 100 mg nightly for a continuous regimen. Some women find it helpful to bring a copy of the relevant NICE guidance or BMS recommendations to the appointment. If your GP is not confident prescribing the switch, a referral to an NHS menopause specialist or a private menopause clinic consultation can facilitate the change. Most women who switch from norethisterone to micronised progesterone report significant improvement in mood, sleep, and general tolerance of their HRT within one to two months.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.